We advised Roivant on the transactions

Davis Polk advised Roivant Sciences Ltd. in connection with a registered direct offering to certain institutional investors of 19,600,685 of its common shares, generating net proceeds of approximately $200 million. Roivant used a portion of the proceeds to make an approximately $170 million investment into its subsidiary Immunovant, Inc. through a private placement of Immunovant common stock that was made concurrently with a public underwritten offering by Immunovant. Davis Polk advised Roivant on the private placement with Immunovant. Roivant’s common shares are listed on the Nasdaq Global Market under the symbol “ROIV” and Immunovant’s common stock is listed on the Nasdaq Global Select Market under the symbol “IMVT.”

Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch “Vants” – nimble and focused biopharmaceutical and health technology companies. Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases.

The Davis Polk corporate team included partners Derek Dostal and Stephen A. Byeff and associate Soo Kyung Chae. Partner Travis Triano provided executive compensation advice. Partners Patrick E. Sigmon and Jonathan Cooklin and associates Yixuan Long, Freddie Schwier and Dmitry Dobrovolskiy provided tax advice. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post